ALK and non-small cell lung carcinoma: For non-small cell lung cancer (NSCLC) the current clinical guidelines recommend testing for genomic alterations in EGFR, BRAF, ROS1, ALK, KRAS, NTRKs, MET, RET, and ERBB2 genes [4,5].